Advertisement

Oral anticoagulant use and clinical outcomes in elderly Japanese patients: findings from the SAKURA AF Registry

  • Toshihiko Nishida
  • Yasuo OkumuraEmail author
  • Katsuaki Yokoyama
  • Naoya Matsumoto
  • Eizo Tachibana
  • Keiichiro Kuronuma
  • Koji Oiwa
  • Michiaki Matsumoto
  • Toshiaki Kojima
  • Shoji Hanada
  • Kazumiki Nomoto
  • Kazumasa Sonoda
  • Ken Arima
  • Rikitake Kogawa
  • Fumiyuki Takahashi
  • Tomobumi Kotani
  • Kimie Ohkubo
  • Seiji Fukushima
  • Satoru Itou
  • Kunio Kondo
  • Masaaki Chiku
  • Yasumi Ohno
  • Motoyuki Onikura
  • Atsushi Hirayama
  • for the SAKURA AF Registry Investigators
Original Article
  • 39 Downloads

Abstract

Direct-acting oral anticoagulants (DOACs) are widely used in aged Japanese patients with atrial fibrillation (AF), but outcome data for such patients are limited. We compared outcomes between 1895 (58.5%) patients aged < 75 years (non-elderly), 1078 (33.3%) 75–84 years (elderly) and 264 (8.2%) ≥ 85 years (very elderly) enrolled in a prospective multicenter registry. Kaplan–Meier analysis (median follow-up: 39.3 months) revealed a significantly high incidence of stroke/systemic embolism (SE) among the very elderly relative to that among the non-elderly or elderly (3.2 vs. 1.2 and 1.5 events per 100 patient-years, p < 0.001). Major bleeding in the non-elderly group was significantly infrequent relative to that among the elderly or very elderly group (1.1 vs. 1.6 vs. 1.8 events, p = 0.033). After multivariate adjustment, the stroke/SE incidence was comparable between DOAC and warfarin users, regardless of age, but major bleeding decreased significantly among very elderly DOAC users (adjusted HR 0.220, 95% CI 0.042–0.920). The greater increasing incidence of stroke/SE than major bleeding as patients age suggests that stroke prevention should outweigh the bleeding risk when anticoagulants are being considered for aged patients. Our data indicated that DOACs can be a therapeutic option for stroke prevention in very elderly patients.

Keywords

Direct oral anticoagulant Warfarin Atrial fibrillation Aged 

Notes

Acknowledgements

The authors thank all centers involved in the study and all patients who consented to enroll in the registry. We also thank Mr. Seiji Udagawa for assistance with the statistical analysis, and we thank Ms. Wendy Alexander-Adams for encouragement and assistance with the reporting of our findings in English.

Funding

The study was supported financially by Bayer Yakuhin Ltd and conducted as an investigator-initiated research project based on a contract with Bayer Yakuhin Ltd. The study was also supported by scholarship funds from Daiichi-Sankyo, Astellas Pharma, Eisai, Sumitomo Dainippon Pharma, MSD, Nihon Medi-Physics, Bristol-Meyers Squibb, Boehringer Ingelheim, and Pfizer.

Compliance with ethical standards

Conflict of interest

Dr. Okumura has accepted remuneration from Daiichi-Sankyo; Dr. Hirayama has received research funding from Bayer Healthcare, Daiichi-Sankyo, Otsuka Pharmaceutical, Astellas Pharma, Eisai, Sumitomo Dainippon Pharma, MSD, Nihon Medi-Physics, Bristol-Meyers Squibb, Boehringer Ingelheim, Pfizer, Boston Scientific Corporation, Hokushin Medical, and has accepted remuneration from Bayer Healthcare, Daiichi-Sankyo, Eisai, Bristol-Meyers Squibb, Astellas Pharma, Sanofi, and Takeda Pharmaceutical; Dr Matsumoto has received research funding from Daiichi-Sankyo, Otsuka Pharmaceutical, and Sumitomo Dainippon Pharma, and has accepted remuneration from Nihon Medi-Physics, FUJIFILM RI Pharma, and Biosensors Interventional Technologies Japan.

References

  1. 1.
    Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, Aizawa Y, Yamashita T, Atarashi H, Horie M, Ohe T, Doi Y, Shimizu A, Chishaki A, Saikawa T, Yano K, Kitabatake A, Mitamura H, Kodama I, Kamakura S (2009) Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol 137:102–107CrossRefGoogle Scholar
  2. 2.
    Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Hanada S, Nomoto K, Arima K, Takahashi F, Kotani T, Ikeya Y, Fukushima S, Itoh S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A, The Sakura Af Registry I (2017) Current use of direct oral anticoagulants for atrial fibrillation in Japan: findings from the SAKURA AF Registry. J Arrhythm 33:289–296CrossRefGoogle Scholar
  3. 3.
    Yamashita Y, Uozumi R, Hamatani Y, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Ogawa H, Abe M, Morita S, Akao M (2017) Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients—Fushimi AF Registry. Circ J 81:1278–1285CrossRefGoogle Scholar
  4. 4.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151CrossRefGoogle Scholar
  5. 5.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891CrossRefGoogle Scholar
  6. 6.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992CrossRefGoogle Scholar
  7. 7.
    Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104CrossRefGoogle Scholar
  8. 8.
    Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M (2013) Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J 77:632–638CrossRefGoogle Scholar
  9. 9.
    Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Hanada S, Nomoto K, Arima K, Takahashi F, Kotani T, Ikeya Y, Fukushima S, Itou S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A (2018) Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation—findings from the SAKURA AF Registry. Circ J 82:2500–2509CrossRefGoogle Scholar
  10. 10.
    Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Arima K, Kotani T, Nomoto K, Ikeya Y, Fukushima S, Onikura M, Suzuki Y, Fujita M, Ando H, Ishikawa N, Hirayama A (2018) Patient satisfaction with direct oral anticoagulants and warfarin. Int Heart J 59:1266–1274CrossRefGoogle Scholar
  11. 11.
    Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236–239CrossRefGoogle Scholar
  12. 12.
    Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H (2016) Beneficial effect of non-vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation- results of the J-RHYTHM Registry 2. Circ J 80:843–851CrossRefGoogle Scholar
  13. 13.
    Akao M, Chun YH, Wada H, Esato M, Hashimoto T, Abe M, Hasegawa K, Tsuji H, Furuke K (2013) Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol 61:260–266CrossRefGoogle Scholar
  14. 14.
    Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F, Murphy SA, Kimura T, Jin J, Lanz H, Mercuri M, Braunwald E, Antman EM (2016) Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc 5:e003432Google Scholar
  15. 15.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123:2363–2372CrossRefGoogle Scholar
  16. 16.
    Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA (2014) Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 130:138–146CrossRefGoogle Scholar
  17. 17.
    Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L (2014) Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 35:1864–1872CrossRefGoogle Scholar
  18. 18.
    Kooistra HA, Calf AH, Piersma-Wichers M, Kluin-Nelemans HC, Izaks GJ, Veeger NJ, Meijer K (2016) Risk of bleeding and thrombosis in patients 70 years or older using vitamin K antagonists. JAMA Intern Med 176:1176–1183CrossRefGoogle Scholar
  19. 19.
    Patti G, Lucerna M, Pecen L, Siller-Matula JM, Cavallari I, Kirchhof P, De Caterina R (2017) Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF thromboembolic events-european registry in atrial fibrillation). J Am Heart Assoc 6:e005657CrossRefGoogle Scholar
  20. 20.
    Murata N, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Hanada S, Nomoto K, Arima K, Takahashi F, Kotani T, Ikeya Y, Fukushima S, Itoh S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A (2019) Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA AF Registry. Circ J 83:727–735CrossRefGoogle Scholar
  21. 21.
    Manzoor BS, Lee TA, Sharp LK, Walton SM, Galanter WL, Nutescu EA (2017) Real-world adherence and persistence with direct oral anticoagulants in adults with atrial fibrillation. Pharmacotherapy 37:1221–1230CrossRefGoogle Scholar
  22. 22.
    Maura G, Pariente A, Alla F, Billionnet C (2017) Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study. Pharmacoepidemiol Drug Saf 26:1367–1377CrossRefGoogle Scholar
  23. 23.
    Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR, Gersh BJ, Shah ND, Noseworthy PA (2016) Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 5:e003074Google Scholar
  24. 24.
    Doggrell SA (2010) Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help? Drugs Aging 27:239–254CrossRefGoogle Scholar
  25. 25.
    Cohen AT, Maillardet L, Yavin Y (2009) Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence? Thromb Haemost 101:422–427CrossRefGoogle Scholar
  26. 26.
    Granziera S, Cohen AT, Nante G, Manzato E, Sergi G (2015) Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm. J Am Med Dir Assoc 16:358–364CrossRefGoogle Scholar
  27. 27.
    Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Lip GYH, Chen SA (2018) Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation 138:37–47CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  • Toshihiko Nishida
    • 1
  • Yasuo Okumura
    • 2
    • 18
    Email author
  • Katsuaki Yokoyama
    • 3
  • Naoya Matsumoto
    • 3
  • Eizo Tachibana
    • 4
  • Keiichiro Kuronuma
    • 4
  • Koji Oiwa
    • 1
  • Michiaki Matsumoto
    • 1
  • Toshiaki Kojima
    • 5
  • Shoji Hanada
    • 6
  • Kazumiki Nomoto
    • 7
  • Kazumasa Sonoda
    • 7
  • Ken Arima
    • 8
  • Rikitake Kogawa
    • 8
  • Fumiyuki Takahashi
    • 9
  • Tomobumi Kotani
    • 10
  • Kimie Ohkubo
    • 11
  • Seiji Fukushima
    • 12
  • Satoru Itou
    • 13
  • Kunio Kondo
    • 14
  • Masaaki Chiku
    • 15
  • Yasumi Ohno
    • 16
  • Motoyuki Onikura
    • 17
  • Atsushi Hirayama
    • 2
  • for the SAKURA AF Registry Investigators
  1. 1.Yokohama Chuo HospitalKanagawaJapan
  2. 2.Division of CardiologyNihon University Itabashi HospitalTokyoJapan
  3. 3.Department of CardiologyNihon University HospitalTokyoJapan
  4. 4.Kawaguchi Municipal Medical CenterSaitamaJapan
  5. 5.Sekishindo HospitalSaitamaJapan
  6. 6.TMG Asakadai Medical CenterSaitamaJapan
  7. 7.Tokyo Rinkai HospitalTokyoJapan
  8. 8.Kasukabe Medical CenterSaitamaJapan
  9. 9.Yasuda HospitalTokyoJapan
  10. 10.Makita General HospitalTokyoJapan
  11. 11.Itabashi Medical Association HospitalTokyoJapan
  12. 12.Ukima Central HospitalTokyoJapan
  13. 13.Itou Cardiovascular ClinicSaitamaJapan
  14. 14.Kondo ClinicTokyoJapan
  15. 15.Keiai ClinicTokyoJapan
  16. 16.Ohno Medical ClinicTokyoJapan
  17. 17.Onikura ClinicChibaJapan
  18. 18.Division of Cardiology, Department of MedicineNihon University School of MedicineTokyoJapan

Personalised recommendations